When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company has to approach the DCGI for approval to commence the trials
First diagnostic centre to open in Mohali on August 31
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The company to receive upfront and milestone payments, in addition to royalties
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
Subscribe To Our Newsletter & Stay Updated
